Cash - Q3 of 2012
1 Report top line results from the Phase 1 clinical trial in advanced
leukemias by the end of 2011,
2 Report top line efficacy analysis results from the randomized Phase 2
trial in pancreatic cancer around the end of 2011,
3 Provide an update on the interim analysis from the pivotal Phase 3
clinical trial of TH-302 plus doxorubicin compared to doxorubicin
alone in patients with metastatic or locally advanced unresectable
soft tissue sarcoma around the end of 2012.
No comments:
Post a Comment